drugset
drugset / Trial / NCT04278248

Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above

NCT04278248 ↗

Phase 3 Completed 1940 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.

Timeline

Start
2018-01-12
Primary completion
2018-06-07
Completion
2018-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pneumovax 23 Vaccine 0.5 ml Intramuscular

Indications

streptococcal pneumonia